IL6 and chronic kidney disease: Recent evidence from the RESCUE trial has further highlighted the potential of anti-inflammatory approaches, as ziltivekimab, an IL-6-targeting antibody, significantly reduced biomarkers of inflammation and thrombosis in CKD patients with elevated CRP levels [192].